Abstract Details

Title Nusinersen in Symptomatic Children with Later-onset Spinal Muscular Atrophy (SMA): Design of the Phase 3 CHERISH Study

Topic Child Neurology and Developmental Neurology

Presentation(s) P3 - (-)

Poster/Presentation
Number 184

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Erica Selheimer, MD PRESENTER	No disclosure on file
Laurence Mignon, PhD (Ionis Pharmaceuticals, Inc)	No disclosure on file
	No disclosure on file
	No disclosure on file
Kathie M. Bishop, PhD	Dr. Bishop has received personal compensation for serving as an employee of Acadia Pharmaceuticals, Inc. . Dr. Bishop has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for DTx Pharma. Dr. Bishop has stock in Acadia Pharmaceuticals, Inc..
	No disclosure on file
Wildon Farwell, MD	Dr. Farwell has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Farwell has received personal compensation for serving as an employee of Satellos Biosciences. Dr. Farwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Paragon Therapeutics. Dr. Farwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Farwell has stock in Dyne Therapeutics. Dr. Farwell has stock in Satellos Bioscience.
Frank Bennett, PhD	No disclosure on file
	No disclosure on file

��ɫ��